Agendia, Inc.: Analysis Presented at SABCS 2021 Confirms MammaPrint and BluePrint Predict Outcomes Following Neoadjuvant Chemotherapy

Data signal importance of serial genomic testing in order to appropriately adjust breast cancer treatment plans Agendia, Inc., a world leader in precision oncology for breast cancer, today shared

Related Keywords

,William Audeh ,Alicep Chung ,Terri Clevenger ,Agendia Inc ,Sinai Medical Center ,Department Of Surgery ,Division Of Surgical Oncology ,Antonio Breast Cancer Symposium ,Cedars Sinai Medical ,Mammaprint High Risk ,Mammaprint Low Risk ,High Risk ,Surgical Oncology ,Low Risk ,Chief Medical Officer ,Mammaprint Risk ,Agendia ,Analysis ,Resented ,Abcs ,021 ,Onfirms ,Mammaprint ,Blueprint ,Redict ,Outcomes ,Following ,Neoadjuvant ,Chemotherapy ,